Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1992 Mar;65(3):369–375. doi: 10.1038/bjc.1992.75

Enhanced 5-fluorouracil cytotoxicity and elevated 5-fluoronucleotides in the rat Walker carcinosarcoma following methotrexate pre-treatment: a 19F-MRS study in vivo.

P M McSheehy 1, M J Prior 1, J R Griffiths 1
PMCID: PMC1977582  PMID: 1558790

Abstract

5-fluorouracil (5FU) is activated intracellularly to cytotoxic 5-fluoronucleotides (FNuct). These were detected non-invasively in rats bearing the Walker carcinosarcoma by 19F-magnetic resonance spectroscopy (MRS) following an i.v. bolus dose of 5FU (50 mg kg-1). Pre-treatment of the rats (3 to 24 h earlier) by methotrexate (MTX) (20 or 50 mg kg-1) did not affect the rate of 5FU disappearance but did significantly increase the rate of FNuct formation (P less than 0.002) and the final amount formed (P less than 0.02) as assessed by MRS in vivo. MTX (20 mg kg-1) caused substantially the same effects on FNuct formation (P less than 0.002 for rate and P less than 0.05 for the amount) when 5FU was administered i.p. although higher doses of 5FU (120 mg kg-1) were necessary to observe the 19F-signals. Quantitative analysis by MRS in vitro of extracts from the freeze-clamped tumours treated by 5FU i.v. confirmed that MTX pre-treatment increased FNuct formation 3-fold (P less than 0.05). Hplc quantitative analysis demonstrated that 50% of the FNuct was the cytotoxic nucleotide FUTP which was also increased 3-fold in MTX treated animals (P less than 0.05). Since the Walker tumour is probably sensitive to 5FU action via FUTP incorporation into RNA, these results suggested that drug regimes in which MTX preceded 5FU (MTX-5FU schedule) would be more cytotoxic that 5FU alone. At an MTX dose of 20 mg kg-1 24 h prior to 5FU there was significant inhibition of growth (P less than 0.05) compared to no treatment, MTX alone or the reverse schedule of 5FU-MTX. These results suggest MRS may be of clinical value in optimising chemotherapy using schedules where MTX precedes 5FU.

Full text

PDF
369

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Benz C., Cadman E. Modulation of 5-fluorouracil metabolism and cytotoxicity by antimetabolite pretreatment in human colorectal adenocarcinoma HCT-8. Cancer Res. 1981 Mar;41(3):994–999. [PubMed] [Google Scholar]
  2. Benz C., Tillis T., Tattelman E., Cadman E. Optimal schedule of methotrexate and 5-fluorouracil in human breast cancer. Cancer Res. 1982 May;42(5):2081–2086. [PubMed] [Google Scholar]
  3. Brown I., Ward H. W. Therapeutic consequences of antitumour drug interactions: methotrexate and 5-fluorouracil in the chemotherapy of C3H mice with transplanted mammary adenocarcinoma. Cancer Lett. 1978 Nov;5(5):291–297. doi: 10.1016/s0304-3835(78)80027-5. [DOI] [PubMed] [Google Scholar]
  4. Cadman E., Heimer R., Benz C. The influence of methotrexate pretreatment on 5-fluorouracil metabolism in L1210 cells. J Biol Chem. 1981 Feb 25;256(4):1695–1704. [PubMed] [Google Scholar]
  5. Damon L. E., Cadman E., Benz C. Enhancement of 5-fluorouracil antitumor effects by the prior administration of methotrexate. Pharmacol Ther. 1989;43(2):155–185. doi: 10.1016/0163-7258(89)90117-4. [DOI] [PubMed] [Google Scholar]
  6. Herrmann R., Kunz W., Osswald H., Ritter M., Port R. The effect of methotrexate pretreatment on 5-fluorouracil kinetics in sarcoma 180 in vivo. Eur J Cancer Clin Oncol. 1985 Jun;21(6):753–758. doi: 10.1016/0277-5379(85)90274-3. [DOI] [PubMed] [Google Scholar]
  7. Houghton J. A., Tice A. J., Houghton P. J. The selectivity of action of methotrexate in combination with 5-fluorouracil in xenografts of human colon adenocarcinomas. Mol Pharmacol. 1982 Nov;22(3):771–778. [PubMed] [Google Scholar]
  8. Hull W. E., Port R. E., Herrmann R., Britsch B., Kunz W. Metabolites of 5-fluorouracil in plasma and urine, as monitored by 19F nuclear magnetic resonance spectroscopy, for patients receiving chemotherapy with or without methotrexate pretreatment. Cancer Res. 1988 Mar 15;48(6):1680–1688. [PubMed] [Google Scholar]
  9. Klubes P., Connelly K., Cerna I., Mandel H. G. Effects of 5-fluorouracil on 5-fluorodeoxyuridine 5'-monophosphate and 2-deoxyuridine 5'-monophosphate pools, and DNA synthesis in solid mouse L1210 and rat Walker 256 tumors. Cancer Res. 1978 Aug;38(8):2325–2331. [PubMed] [Google Scholar]
  10. Mackintosh J., Tattersall M. H. Biochemical modulation of fluorouracil therapy in advanced colorectal cancer. Ann Acad Med Singapore. 1987 Jul;16(3):444–448. [PubMed] [Google Scholar]
  11. Marsh J. C., Bertino J. R., Katz K. H., Davis C. A., Durivage H. J., Rome L. S., Richards F., 2nd, Capizzi R. L., Farber L. R., Pasquale D. N. The influence of drug interval on the effect of methotrexate and fluorouracil in the treatment of advanced colorectal cancer. J Clin Oncol. 1991 Mar;9(3):371–380. doi: 10.1200/JCO.1991.9.3.371. [DOI] [PubMed] [Google Scholar]
  12. McSheehy P. M., Griffiths J. R. 19F MRS studies of fluoropyrimidine chemotherapy. A review. NMR Biomed. 1989 Nov;2(4):133–141. doi: 10.1002/nbm.1940020402. [DOI] [PubMed] [Google Scholar]
  13. McSheehy P. M., Maxwell R. J., Griffiths J. R. Detection of differential sensitivity to 5-fluorouracil in Ehrlich ascites tumour cells by 19F NMR spectroscopy. NMR Biomed. 1991 Dec;4(6):274–278. doi: 10.1002/nbm.1940040605. [DOI] [PubMed] [Google Scholar]
  14. McSheehy P. M., Prior M. J., Griffiths J. R. Prediction of 5-fluorouracil cytotoxicity towards the Walker carcinosarcoma using peak integrals of fluoronucleotides measured by MRS in vivo. Br J Cancer. 1989 Sep;60(3):303–309. doi: 10.1038/bjc.1989.275. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Pinedo H. M., Peters G. F. Fluorouracil: biochemistry and pharmacology. J Clin Oncol. 1988 Oct;6(10):1653–1664. doi: 10.1200/JCO.1988.6.10.1653. [DOI] [PubMed] [Google Scholar]
  16. Prior M. J., Maxwell R. J., Griffiths J. R. In vivo 19F NMR spectroscopy of the antimetabolite 5-fluorouracil and its analogues. An assessment of drug metabolism. Biochem Pharmacol. 1990 Mar 1;39(5):857–863. doi: 10.1016/0006-2952(90)90200-5. [DOI] [PubMed] [Google Scholar]
  17. Schwartz P. M., Handschumacher R. E. Selective antagonism of 5-fluorouracil cytotoxicity by 4-hydroxypyrazolopyrimidine (allopurinol) in vitro. Cancer Res. 1979 Aug;39(8):3095–3101. [PubMed] [Google Scholar]
  18. Semmler W., Bachert-Baumann P., Gückel F., Ermark F., Schlag P., Lorenz W. J., van Kaick G. Real-time follow-up of 5-fluorouracil metabolism in the liver of tumor patients by means of F-19 MR spectroscopy. Radiology. 1990 Jan;174(1):141–145. doi: 10.1148/radiology.174.1.2104675. [DOI] [PubMed] [Google Scholar]
  19. Sijens P. E., Huang Y. M., Baldwin N. J., Ng T. C. 19F magnetic resonance spectroscopy studies of the metabolism of 5-fluorouracil in murine RIF-1 tumors and liver. Cancer Res. 1991 Mar 1;51(5):1384–1390. [PubMed] [Google Scholar]
  20. Stevens A. N., Morris P. G., Iles R. A., Sheldon P. W., Griffiths J. R. 5-fluorouracil metabolism monitored in vivo by 19F NMR. Br J Cancer. 1984 Jul;50(1):113–117. doi: 10.1038/bjc.1984.146. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Vialaneix J. P., Chouini N., Malet-Martino M. C., Martino R., Michel G., Lepargneur J. P. Noninvasive and quantitative 19F nuclear magnetic resonance study of flucytosine metabolism in Candida strains. Antimicrob Agents Chemother. 1986 Nov;30(5):756–762. doi: 10.1128/aac.30.5.756. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES